DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Angeliq Regulatory Post Marketing Surveillance

Information source: Bayer
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Postmenopausal Period; Osteoporosis, Postmenopausal

Intervention: E2/DRSP (Angeliq, BAY86-4891) (Drug)

Phase: N/A

Status: Completed

Sponsored by: Bayer

Official(s) and/or principal investigator(s):
Bayer Study Director, Study Director, Affiliation: Bayer


Angeliq regulatory Post-Marketing Surveillance (PMS) is to get data about safety and efficacy in real practice for the indication approved by Korea Food and Drug Administration (KFDA). This is non-interventional , prospective, multi-center study. Target number of patients is 4500.

Clinical Details

Official title: Angeliq Regulatory Post Marketing Surveillance

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome: Adverse event collection

Secondary outcome: Improvement of menopausal symptoms


Minimum age: N/A. Maximum age: N/A. Gender(s): Female.


Inclusion Criteria:

- Hormone replacement therapy for estrogen deficiency symptoms in postmenopausal women

more than 1 year postmenopause

- Prevention of osteoporosis in postmenopausal women at high risk of future fractures

who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of osteoporosis Exclusion Criteria:

- Undiagnosed genital bleeding

- Known, past or suspected cancer of the breast

- Known or suspected estrogen-dependent malignant tumors (e. g. endometrial cancer)

- Untreated endometrial hyperplasia

- Previous idiopathic or current venous thromboembolism (e. g. deep venous thrombosis,

pulmonary embolism)

- Active or recent arterial thromboembolic disease (e. g. angina, myocardial infarction)

- Acute liver disease, or a history of liver disease as long as liver function tests

have failed to return to normal

- Porphyria

- Severe renal insufficiency or acute renal failure

- Known hypersensitivity to the active substances or to any of the excipients

Locations and Contacts

Many Locations, Korea, Republic of
Additional Information

Click here and search for drug information provided by the FDA.

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.

Starting date: June 2007
Last updated: November 18, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017